Compare OCC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | EQ |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.0M | 129.0M |
| IPO Year | 2001 | 2018 |
| Metric | OCC | EQ |
|---|---|---|
| Price | $16.92 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 380.2K | ★ 1.0M |
| Earning Date | 06-04-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,828,590.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $4.02 | $0.36 |
| 52 Week High | $27.98 | $3.54 |
| Indicator | OCC | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 45.38 |
| Support Level | $4.80 | $1.68 |
| Resistance Level | $27.98 | $3.50 |
| Average True Range (ATR) | 1.58 | 0.27 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 49.02 | 27.96 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.